Onchocerca volvulus: The Road from Basic Biology to a Vaccine

Trends in Parasitology

Volumn 34, Issue 1, 2018, Pages 64-79

  Lustigman, Sara ^a   Makepeace, Benjamin L ^b   Klei, Thomas R ^c   Babayan, Simon A ^d   Hotez, Peter ^e   Abraham, David ^f   Bottazzi, Maria Elena ^e  

^a NEW YORK BLOOD CENTER   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

elimination; Onchocerca volvulus; vaccine; vaccine candidates

Indexed keywords

IVERMECTIN; MICROORGANISM PROTEIN; ONCHOCERCA VOLVULUS VACCINE; PARASITE ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE; ANTIPARASITIC AGENT;

DECISION SUPPORT SYSTEM; DRUG DESIGN; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; MACHINE LEARNING; NONHUMAN; OMICS; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PROTEIN ANALYSIS; REVIEW; VACCINATION; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; IMMUNOLOGY; OCULAR ONCHOCERCIASIS; STANDARDS; TRANSMISSION;

ANIMALS; ANTIPARASITIC AGENTS; DRUG RESISTANCE; HUMANS; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS, OCULAR; VACCINES;

EID: 85029680546     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2017.08.011     Document Type: Review

References (92)

1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 310 Diseases and Injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1545–1602.
2. Hotez, P.J., et al. The Onchocerciasis Vaccine For Africa—TOVA​—initiative. PLoS Negl. Trop. Dis., 9, 2015, e0003422.
3. Doyle, S.R., et al. Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity. PLoS Negl. Trop. Dis., 11, 2017, e0005816.
4. Kim, Y.E., et al. Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. PLoS Negl. Trop. Dis., 9, 2015, e0003664.
5. Lange, A.M., et al. Induction of protective immunity against larval Onchocerca volvulus in a mouse model. Am. J. Trop. Med. Hyg. 49 (1993), 783–788.
6. Babayan, S.A., et al. Vaccination against filarial nematodes with irradiated larvae provides long-term protection against the third larval stage but not against subsequent life cycle stages. Int. J. Parasitol. 36 (2006), 903–914.
7. Tchakoute, V.L., et al. In a bovine model of onchocerciasis, protective immunity exists naturally, is absent in drug-cured hosts, and is induced by vaccination. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 5971–5976.
8. Achukwi, M.D., et al. Successful vaccination against Onchocerca ochengi infestation in cattle using live Onchocerca volvulus infective larvae. Parasite Immunol. 29 (2007), 113–116.
9. Le Goff, L., et al. Parasitology and immunology of mice vaccinated with irradiated Litomosoides sigmodontis larvae. Parasitology 120 (2000), 271–280.
10. Turner, H.C., et al. Human onchocerciasis: modelling the potential long-term consequences of a vaccination programme. PLoS Negl. Trop. Dis., 9, 2015, e0003938.
11. Lustigman, S., et al. CD4+ dependent immunity to Onchocerca volvulus third-stage larvae in humans and the mouse vaccination model: common ground and distinctions. Int. J. Parasitol. 33 (2003), 1161–1171.
12. Abraham, D., et al. Development of a recombinant antigen vaccine against infection with the filarial worm Onchocerca volvulus. Infect. Immun. 69 (2001), 262–270.
13. Lustigman, S., et al. Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends Parasitol. 18 (2002), 135–141.
14. Sher, A., Vaccination against parasites: special problems imposed by the adaptation of parasitic organisms to the host immune response. Englund, P.T., Sher, A., (eds.) The Biology of Parasitism, 1988, Alan R. Liss, 169–182.
15. Henkle-Duhrsen, K., Kampkotter, A., Antioxidant enzyme families in parasitic nematodes. Mol. Biochem. Parasitol. 114 (2001), 129–142.
16. Wu, Y., et al. Chitinase genes expressed by infective larvae of the filarial nematodes, Acanthocheilonema viteae and Onchocerca volvulus. Mol. Biochem. Parasitol. 75 (1996), 207–219.
17. Lizotte-Waniewski, M., et al. Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of Onchocerca volvulus larval cDNA libraries. Infect. Immun. 68 (2000), 3491–3501.
18. Harrison, R.A., et al. DNA immunisation with Onchocerca volvulus chitinase induces partial protection against challenge infection with L3 larvae in mice. Vaccine 18 (1999), 647–655.
19. Lustigman, S., Abraham, D., Onchocerciasis. Barrett, A.D.T., Stanberry, L.R., (eds.) Vaccines for Biodefense and Emerging and Neglected Diseases, 2008, Academic Press, 1379–1400.
20. Tawe, W., et al. Angiogenic activity of Onchocerca volvulus recombinant proteins similar to vespid venom antigen 5. Mol. Biochem. Parasitol. 109 (2000), 91–99.
21. Makepeace, B.L., Tanya, V.N., 25 Years of the Onchocerca ochengi model. Trends Parasitol. 32 (2016), 966–978.
22. Makepeace, B.L., et al. Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure. PLoS Negl. Trop. Dis., 3, 2009, e544.
23. Erttmann, K.D., et al. Cloning, characterization and DNA immunization of an Onchocerca volvulus glyceraldehyde-3-phosphate dehydrogenase (Ov-GAPDH). Biochim. Biophys. Acta 1741 (2005), 85–94.
24. Abraham, D., et al. Survival and development of larval Onchocerca volvulus in diffusion chambers implanted in primate and rodent hosts. J. Parasitol. 79 (1993), 571–582.
25. Morris, C.P., et al. A comprehensive, model-based review of vaccine and repeat infection trials for filariasis. Clin. Microbiol. Rev. 26 (2013), 381–421.
26. Hess, J.A., et al. Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. Int. J. Parasitol. 44 (2014), 637–646.
27. Frank, G.R., et al. Molecular cloning of a developmentally regulated protein isolated from excretory-secretory products of larval Dirofilaria immitis. Mol. Biochem. Parasitol. 75 (1996), 231–240.
28. Gregory, W.F., et al. The abundant larval transcript-1 and -2 genes of Brugia malayi encode stage-specific candidate vaccine antigens for filariasis. Infect. Immun. 68 (2000), 4174–4179.
29. Anand, S.B., et al. Comparison of immuno prophylactic efficacy of Bm rALT2 or Bm rVAH or rALT + rVAH by single and multiple antigen vaccination mode. Am. J. Trop. Med. Hyg., 75, 2006, 295.
30. Pfaff, A.W., et al. Litomosoides sigmodontis cystatin acts as an immunomodulator during experimental filariasis. Int. J. Parasitol. 32 (2002), 171–178.
31. Lustigman, S., et al. Characterization of an Onchocerca volvulus cDNA clone encoding a genus specific antigen present in infective larvae and adult worms. Mol. Biochem. Parasitol. 45 (1991), 65–75.
32. Lustigman, S., et al. Molecular cloning and characterization of onchocystatin, a cysteine proteinase inhibitor of Onchocerca volvulus. J. Biol. Chem. 267 (1992), 17339–17346.
33. Ramachandran, S., et al. The larval specific lymphatic filarial ALT-2: induction of protection using protein or DNA vaccination. Microbiol. Immunol. 48 (2004), 945–955.
34. Wang, S.H., et al. Evaluation of recombinant chitinase and SXP1 antigens as antimicrofilarial vaccines. Am. J. Trop. Med. Hyg. 56 (1997), 474–481.
35. Adam, R., et al. Identification of chitinase as the immunodominant filarial antigen recognized by sera of vaccinated rodents. J. Biol. Chem. 271 (1996), 1441–1447.
36. Taylor, M.J., et al. Onchocerca volvulus larval antigen, OvB20, induces partial protection in a rodent model of onchocerciasis. Infect. Immun. 63 (1995), 4417–4422.
37. Jenkins, R.E., et al. Characterization of a secreted antigen of Onchocerca volvulus with host-protective potential. Parasite Immunol. 18 (1996), 29–42.
38. Ghosh, K., et al. Vaccination with alum-precipitated recombinant Ancylostoma-secreted protein 1 protects mice against challenge infections with infective hookworm (Ancylostoma caninum) larvae. J. Infect. Dis. 174 (1996), 1380–1383.
39. Goud, G.N., et al. Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trials. Vaccine 23 (2005), 4754–4764.
40. Hotez, P.J., et al. New technologies for the control of human hookworm infection. Trends Parasitol. 22 (2006), 327–331.
41. Bethony, J.M., et al. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults. Vaccine 26 (2008), 2408–2417.
42. Zhan, B., et al. Ac-SAA-1, an immunodominant 16 kDa surface-associated antigen of infective larvae and adults of Ancylostoma caninum. Int. J. Parasitol. 34 (2004), 1037–1045.
43. Tsuji, N., et al. Intranasal immunization with recombinant Ascaris suum 14-kilodalton antigen coupled with cholera toxin B subunit induces protective immunity to A. suum infection in mice. Infect. Immun. 69 (2001), 7285–7792.
44. Tsuji, N., et al. Mice intranasally immunized with a recombinant 16-kilodalton antigen from roundworm Ascaris parasites are protected against larval migration of Ascaris suum. Infect. Immun. 71 (2003), 5314–5323.
45. Tsuji, N., et al. Recombinant Ascaris 16-kilodalton protein-induced protection against Ascaris suum larval migration after intranasal vaccination in pigs. J. Infect. Dis. 190 (2004), 1812–1820.
46. Arumugam, S., et al. Vaccination of gerbils with Bm-103 and Bm-RAL-2 concurrently or as a fusion protein confers consistent and improved protection against Brugia malayi infection. PLoS Negl. Trop. Dis., 10, 2016, e0004586.
47. Johnson, E.H., et al. Immune responses to third stage larvae of Onchocerca volvulus in interferon-gamma and interleukin-4 knockout mice. Parasite Immunol. 20 (1998), 319–324.
48. Lange, A.M., et al. IL-4- and IL-5-dependent protective immunity to Onchocerca volvulus infective larvae in BALB/cBYJ mice. J. Immunol. 153 (1994), 205–211.
49. Abraham, D., et al. Immunoglobulin E and eosinophil-dependent protective immunity to larval Onchocerca volvulus in mice immunized with irradiated larvae. Infect. Immun. 72 (2004), 810–817.
50. Volkmann, L., et al. Interleukin-4 is essential for the control of microfilariae in murine infection with the filaria Litomosoides sigmodontis. Infect. Immun. 69 (2001), 2950–2956.
51. Martin, C., et al. IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. Med. Microbiol. Immunol. 189 (2000), 67–74.
52. Specht, S., et al. Lack of eosinophil peroxidase or major basic protein impairs defense against murine filarial infection. Infect. Immun. 74 (2006), 5236–5243.
53. Saeftel, M., et al. Synergism of gamma interferon and interleukin-5 in the control of murine filariasis. Infect. Immun. 71 (2003), 6978–6985.
54. Hubner, M.P., et al. Type 2 immune-inducing helminth vaccination maintains protective efficacy in the setting of repeated parasite exposures. Vaccine 28 (2010), 1746–1757.
55. Hess, J.A., et al. The immunomodulatory role of adjuvants in vaccines formulated with the recombinant antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in mice. PLoS Negl. Trop. Dis., 10, 2016, e0004797.
56. Babayan, S.A., et al. Deletion of parasite immune modulatory sequences combined with immune activating signals enhances vaccine mediated protection against filarial nematodes. PLoS Negl. Trop. Dis., 6, 2012, e1968.
57. Allen, J.E., et al. Of mice, cattle, and humans: the immunology and treatment of river blindness. PLoS Negl. Trop. Dis., 2, 2008, e217.
58. Pedrique, B., et al. The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment. Lancet Glob. Health 1 (2013), e371–e379.
59. Pronker, E.S., et al. Risk in vaccine research and development quantified. PLoS One, 8, 2013, e57755.
60. Nabel, G.J., Designing tomorrow's vaccines. N. Engl. J. Med. 368 (2013), 551–560.
61. De Gregorio, E., Rappuoli, R., From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat. Rev. Immunol. 14 (2014), 505–514.
62. Rueckert, C., Guzman, C.A., Vaccines: from empirical development to rational design. PLoS Pathog., 8, 2012, e1003001.
63. Griffin, J.F., A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery. Adv. Drug Deliv. Rev. 54 (2002), 851–861.
64. Lustigman, S., et al. The role of ‘omics’ in the quest to eliminate human filariasis. PLoS Negl. Trop. Dis., 11, 2017, e0005464.
65. Bennuru, S., et al. Brugia malayi excreted/secreted proteins at the host/parasite interface: stage- and gender-specific proteomic profiling. PLoS Negl. Trop. Dis., 3, 2009, e410.
66. Armstrong, S.D., et al. Comparative analysis of the secretome from a model filarial nematode (Litomosoides sigmodontis) reveals maximal diversity in gravid female parasites. Mol. Cell. Proteom. 13 (2014), 2527–2544.
67. Armstrong, S.D., et al. Stage-specific proteomes from Onchocerca ochengi, sister species of the human river blindness parasite, uncover adaptations to a nodular lifestyle. Mol. Cell. Proteom. 15 (2016), 2554–2575.
68. Chhabra, S., et al. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J. 28 (2014), 3952–3964.
69. Arumugam, S., et al. Vaccination with a genetically modified Brugia malayi cysteine protease inhibitor-2 reduces adult parasite numbers and affects the fertility of female worms following a subcutaneous challenge of Mongolian gerbils (Meriones unguiculatus) with B. malayi infective larvae. Int. J. Parasitol. 44 (2014), 675–679.
70. Cotton, J.A., et al. The genome of Onchocerca volvulus, agent of river blindness. Nat. Microbiol., 2, 2016, 16216.
71. Bennuru, S., et al. Stage-specific transcriptome and proteome analyses of the filarial parasite Onchocerca volvulus and its Wolbachia endosymbiont. mBio, 7, 2016 e02028-16.
72. de Assis, R.R., et al. A next-generation proteome array for Schistosoma mansoni. Int. J. Parasitol. 46 (2016), 411–415.
73. Driguez, P., et al. Schistosomiasis vaccine discovery using immunomics. Parasit. Vectors, 3, 2010, 4.
74. Doolan, D.L., et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 8 (2008), 4680–4694.
75. Gaze, S., et al. An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas. PLoS Pathog., 10, 2014, e1004033.
76. Tang, Y.T., et al. Genome of the human hookworm Necator americanus. Nat. Genet. 46 (2014), 261–269.
77. Bacarese-Hamilton, T., et al. Protein microarrays: from serodiagnosis to whole proteome scale analysis of the immune response against pathogenic microorganisms. Biotechniques 33:Suppl (2002), S24–S29.
78. Lagatie, O., et al. Identification of three immunodominant motifs with atypical isotype profile scattered over the Onchocerca volvulus proteome. PLoS Negl. Trop. Dis., 11, 2017, e0005330.
79. Hoerauf, A., Brattig, N., Resistance and susceptibility in human onchocerciasis – beyond Th1 vs. Th2. Trends Parasitol. 18 (2002), 25–31.
80. Babayan, S.A., et al. Future prospects and challenges of vaccines against filariasis. Parasite Immunol. 34 (2012), 243–253.
81. Katawa, G., et al. Hyperreactive onchocerciasis is characterized by a combination of Th17-Th2 immune responses and reduced regulatory T cells. PLoS Negl. Trop. Dis., 9, 2015, e3414.
82. Brattig, N.W., Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Microbes Infect. 6 (2004), 113–128.
83. Meyer, C.G., et al. HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 7515–7519.
84. Hoerauf, A., et al. The variant Arg110Gln of human IL-13 is associated with an immunologically hyper-reactive form of onchocerciasis (sowda). Microbes Infect. 4 (2002), 37–42.
85. Keiser, P.B., et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J. Infect. Dis. 185 (2002), 805–811.
86. Wildenburg, G., et al. Lymph nodes of onchocerciasis patients after treatment with ivermectin: reaction of eosinophil granulocytes and their cationic granule proteins. Trop. Med. Parasitol. 45 (1994), 87–96.
87. Zhang, J., et al. Machine-learning algorithms define pathogen-specific local immune fingerprints in peritoneal dialysis patients with bacterial infections. Kidney Int. 92 (2017), 179–191.
88. Hastie, T., et al. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. 10th edn., 2009, Springer.
89. Urrutia, A., et al. Standardized whole-blood transcriptional profiling enables the deconvolution of complex induced immune responses. Cell Rep. 16 (2016), 2777–2791.
90. Hotez, P.J., et al. Human anthelminthic vaccines: rationale and challenges. Vaccine 34 (2016), 3549–3555.
91. Diemert, D.J., et al. Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. PLoS Negl. Trop. Dis., 11, 2017, e0005574.
92. Merrifield, M., et al. Advancing a vaccine to prevent human schistosomiasis. Vaccine 34 (2016), 2988–2991.